You are here

  • Home
  • Archive
  • Volume 10, Issue Suppl 2
  • 172 Body mass index (BMI) and serum albumin level as a predictor of survival outcomes in advanced-stage melanoma patients treated with anti-PD1 therapy

Citation Tools

Article menu

Download PDFPDF

Regular and Young Investigator Award Abstracts
Biomarkers, Immune Monitoring and Novel Technologies
172 Body mass index (BMI) and serum albumin level as a predictor of survival outcomes in advanced-stage melanoma patients treated with anti-PD1 therapy
Free

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Mohamoud Y, Park Y, Tesfamichael D, et al
172 Body mass index (BMI) and serum albumin level as a predictor of survival outcomes in advanced-stage melanoma patients treated with anti-PD1 therapy
Journal for ImmunoTherapy of Cancer 2022;10:doi: 10.1136/jitc-2022-SITC2022.0172